Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years ...

Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.

Mounjaro and Zepbound will continue to be crucial to Eli Lilly's progress. Here are two key things to watch. First, how quickly are their sales continuing to grow?

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight ...

Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy Gilmore 2” star.

About Eli Lilly Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance ...

Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana.

Eli Lilly and Company (NYSE:LLY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twenty brokerages that are covering the stock, MarketBeat.com reports ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...